Ironwood Pharmaceuticals: High Dependence On Its Next Trial

Ironwood Pharmaceuticals is a small-cap GI-focused biotech with strong LINZESS sales but looming patent expiry by 2029–2030. IRWD raised LINZESS full-year U.S. net sales guidance to $1.15–$1.2 billion and its own revenue forecast to $460–$485 million. Apraglutide, IRWD's pipeline asset for SBS-IF, showed statistically significant Phase 3 results and is key to future value.

Seeking Alpha • Aug 26, 2026

Ironwood Q2 Earnings Beat Estimates, Revenues Lag, 2026 View Raised

IRWD tops Q2 earnings estimates, misses on revenues and lifts its 2026 outlook as strong Linzess demand drives year-over-year growth.

Zacks Investment Research • Aug 7, 2026

Ironwood Pharmaceuticals Q2 Earnings Call Highlights

Ironwood Pharmaceuticals NASDAQ: IRWD reported second-quarter results marked by higher LINZESS sales, the start of enrollment in its confirmatory Phase III study of apraglutide, and repayment of its convertible notes, prompting the company to raise its full-year 2026 financial outlook.

MarketBeat • Aug 6, 2026

Ironwood Pharmaceuticals, Inc. (IRWD) Q2 2026 Earnings Call Transcript

Ironwood Pharmaceuticals, Inc. (IRWD) Q2 2026 Earnings Call Transcript

Seeking Alpha • Aug 6, 2026

Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its second quarter 2026 results and recent business performance. “Throughout the first half of the year, we have remained laser focused on meaningful execution of our three strategic priorities: maximizing LINZESS, advancing apraglutide, and delivering sustained profit.

Business Wire • Aug 6, 2026

Ironwood Pharmaceuticals (IRWD) Q2 Earnings Top Estimates

Ironwood Pharmaceuticals (IRWD) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.26 per share. This compares to earnings of $0.14 per share a year ago.

Zacks Investment Research • Aug 6, 2026

Buy The Dip: 2 Top Undervalued Stocks Averaging 394% Forward EPS Growth

Despite the recent market selloff, earnings expectations continue to rise: The S&P 500's Q2 EPS is projected to grow by 37.9%, while net profit margins could reach a 15-year high. Buying the dip can present opportunities for investors. When fear fades, markets have historically returned to fundamentals. Using Seeking Alpha's Quant Tools, I found two Strong Buy stocks, beaten down in the past month, offering both solid growth and value.

Seeking Alpha • Jul 31, 2026

Ironwood Pharmaceuticals to Host Second Quarter 2026 Investor Update Call

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), today announced it will host its second quarter 2026 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, August 6, 2026. Individuals interested in participating in the call should dial (888) 596-4144 (U.S.) or (646) 968-2525 (international) using conference ID number and event passcode 3647053. To access the webcast, please visit the Investors & Media section of Ironwood's website at www.i.

Business Wire • Jul 30, 2026

Ironwood Pharmaceuticals: One Trial Stands Between Bargain And Bust

Ironwood Pharmaceuticals trades at a 40% discount to its risk-adjusted sum-of-the-parts valuation, anchored by LINZESS and apraglutide. I assign a 'Buy' rating on IRWD and a $6.3 price target, citing a margin of safety, but I also warn of a binary risk tied to apraglutide's pivotal trial. LINZESS faces a patent cliff in 2029, with revenue projected to decay rapidly following the entry of generic products.

Seeking Alpha • Jul 30, 2026

Here's Why Ironwood Pharmaceuticals (IRWD) is a Strong Momentum Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Jul 15, 2026